Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs LTC Properties Inc (LTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs LTC Properties Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while LTC Properties Inc trades at $39.06 (market cap $1.99B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 20× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.87% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LTC | |
|---|---|---|
Market Cap | $39.89B | $1.99B |
Sector | Health | Real Estate |
52-Week High | $491.22 | $40.36 |
52-Week Low | $278.09 | $33.98 |
Enterprise Value | $38.15B | $2.84B |
Dividend Yield | — | 5.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
LTC Properties trades at $38.86, down 0.72% on the day, with a bullish technical signal from moving averages and a neutral RSI. The REIT shows strong profitability with a 39.09% net income margin and a P/E of 15.24. Recent acquisitions, including a $73 million SHOP portfolio expansion (Business Wire, 2026-07-08), highlight growth initiatives, while consistent monthly dividends of $0.19 provide income appeal.
The outlook is mixed: analyst consensus leans Hold (59.09%) amid recent earnings misses, but bullish technicals and strategic shifts to seniors housing offer upside. Risks include execution on SHOP transitions and debt levels, with net cash flow turning negative in 2026. Investors should weigh growth potential against margin pressures and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →
